Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study
ObjectiveTo investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycem...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.1051958/full |
| _version_ | 1797954131172786176 |
|---|---|
| author | María Teresa Julián Sílvia Ballesta Guillem Pera Alejandra Pérez-Montes de Oca Berta Soldevila Berta Soldevila Llorenç Caballería Llorenç Caballería Rosa Morillas Rosa Morillas Carmen Expósito Carmen Expósito Alba Martínez–Escudé Alba Martínez–Escudé Manel Puig-Domingo Manel Puig-Domingo Manel Puig-Domingo Josep Franch-Nadal Josep Franch-Nadal Pere Torán Pere Torán Kenneth Cusi Josep Julve Josep Julve Josep Julve Dídac Mauricio Dídac Mauricio Dídac Mauricio Núria Alonso Núria Alonso Núria Alonso |
| author_facet | María Teresa Julián Sílvia Ballesta Guillem Pera Alejandra Pérez-Montes de Oca Berta Soldevila Berta Soldevila Llorenç Caballería Llorenç Caballería Rosa Morillas Rosa Morillas Carmen Expósito Carmen Expósito Alba Martínez–Escudé Alba Martínez–Escudé Manel Puig-Domingo Manel Puig-Domingo Manel Puig-Domingo Josep Franch-Nadal Josep Franch-Nadal Pere Torán Pere Torán Kenneth Cusi Josep Julve Josep Julve Josep Julve Dídac Mauricio Dídac Mauricio Dídac Mauricio Núria Alonso Núria Alonso Núria Alonso |
| author_sort | María Teresa Julián |
| collection | DOAJ |
| description | ObjectiveTo investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia.Material and MethodsA longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively.ResultsAmong 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa.ConclusionsIn this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD. |
| first_indexed | 2024-04-10T23:12:46Z |
| format | Article |
| id | doaj.art-e2c848f3b14c40caa62733ffa3ae82cb |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-10T23:12:46Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-e2c848f3b14c40caa62733ffa3ae82cb2023-01-13T04:45:22ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-01-011310.3389/fendo.2022.10519581051958Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based studyMaría Teresa Julián0Sílvia Ballesta1Guillem Pera2Alejandra Pérez-Montes de Oca3Berta Soldevila4Berta Soldevila5Llorenç Caballería6Llorenç Caballería7Rosa Morillas8Rosa Morillas9Carmen Expósito10Carmen Expósito11Alba Martínez–Escudé12Alba Martínez–Escudé13Manel Puig-Domingo14Manel Puig-Domingo15Manel Puig-Domingo16Josep Franch-Nadal17Josep Franch-Nadal18Pere Torán19Pere Torán20Kenneth Cusi21Josep Julve22Josep Julve23Josep Julve24Dídac Mauricio25Dídac Mauricio26Dídac Mauricio27Núria Alonso28Núria Alonso29Núria Alonso30Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, SpainUnitat de Suport a la Recerca (USR) Metropolitana Nord, Fundació Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), Mataró, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, SpainDepartment of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainUnitat de Suport a la Recerca (USR) Metropolitana Nord, Fundació Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), Mataró, SpainCentro d’Investigaciones Biomédicas en Red, Enfermedades Hepatologia y Digestivas, Barcelona, SpainCentro d’Investigaciones Biomédicas en Red, Enfermedades Hepatologia y Digestivas, Barcelona, SpainHepatology Department, Hospital Germans Trias I Pujol, Badalona, Barcelona, SpainUnitat de Suport a la Recerca (USR) Metropolitana Nord, Fundació Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), Mataró, SpainCentro d’Investigaciones Biomédicas en Red, Enfermedades Hepatologia y Digestivas, Barcelona, SpainUnitat de Suport a la Recerca (USR) Metropolitana Nord, Fundació Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), Mataró, SpainPrimary Care, Centre d’Atenció Primària La Llagosta, Institut Català de la Salut, Barcelona, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, SpainDepartment of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainCenter for Biomedical Research on Diabetes and Associated Metabolic diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, SpainCenter for Biomedical Research on Diabetes and Associated Metabolic diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, SpainPrimary Health Care Center Raval Sud, Gerència d’Atenció Primaria, Institut Català de la Salut, Barcelona, SpainUnitat de Suport a la Recerca (USR) Metropolitana Nord, Fundació Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina (IDIAP Jordi Gol), Mataró, SpainCentro d’Investigaciones Biomédicas en Red, Enfermedades Hepatologia y Digestivas, Barcelona, SpainDivision of Endocrinology, Diabetes and Metabolism. University of Florida, Gainesville, FL, United StatesCenter for Biomedical Research on Diabetes and Associated Metabolic diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain0Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau; Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain1Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, SpainCenter for Biomedical Research on Diabetes and Associated Metabolic diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain0Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau; Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain2Faculty of Medicine, University of Vic, Central University of Catalonia, Vic, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, SpainDepartment of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainCenter for Biomedical Research on Diabetes and Associated Metabolic diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, SpainObjectiveTo investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia.Material and MethodsA longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively.ResultsAmong 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa.ConclusionsIn this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.https://www.frontiersin.org/articles/10.3389/fendo.2022.1051958/fullliver fibrosisNAFLDTransient elastographyabdominal obesitydysglycemiageneral population |
| spellingShingle | María Teresa Julián Sílvia Ballesta Guillem Pera Alejandra Pérez-Montes de Oca Berta Soldevila Berta Soldevila Llorenç Caballería Llorenç Caballería Rosa Morillas Rosa Morillas Carmen Expósito Carmen Expósito Alba Martínez–Escudé Alba Martínez–Escudé Manel Puig-Domingo Manel Puig-Domingo Manel Puig-Domingo Josep Franch-Nadal Josep Franch-Nadal Pere Torán Pere Torán Kenneth Cusi Josep Julve Josep Julve Josep Julve Dídac Mauricio Dídac Mauricio Dídac Mauricio Núria Alonso Núria Alonso Núria Alonso Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study Frontiers in Endocrinology liver fibrosis NAFLD Transient elastography abdominal obesity dysglycemia general population |
| title | Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study |
| title_full | Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study |
| title_fullStr | Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study |
| title_full_unstemmed | Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study |
| title_short | Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study |
| title_sort | abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in nafld subjects a population based study |
| topic | liver fibrosis NAFLD Transient elastography abdominal obesity dysglycemia general population |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.1051958/full |
| work_keys_str_mv | AT mariateresajulian abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT silviaballesta abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT guillempera abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT alejandraperezmontesdeoca abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT bertasoldevila abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT bertasoldevila abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT llorenccaballeria abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT llorenccaballeria abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT rosamorillas abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT rosamorillas abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT carmenexposito abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT carmenexposito abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT albamartinezescude abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT albamartinezescude abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT manelpuigdomingo abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT manelpuigdomingo abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT manelpuigdomingo abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT josepfranchnadal abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT josepfranchnadal abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT peretoran abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT peretoran abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT kennethcusi abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT josepjulve abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT josepjulve abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT josepjulve abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT didacmauricio abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT didacmauricio abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT didacmauricio abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT nuriaalonso abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT nuriaalonso abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy AT nuriaalonso abdominalobesityanddsyglycemiaareriskfactorsforliverfibrosisprogressioninnafldsubjectsapopulationbasedstudy |